Keyword: PCSK9

human heart

Special Report—The top 10 cardiovascular drugs in the world

Cardiovascular drugs may not be the top field in terms of sales or market growth rate. But heart disease and related ailments remain the biggest cause of death in the U.S. We’ve put together this list as a state-of-the-market snapshot, coinciding with the European Society of Cardiology meeting this week.
bradway

15. Robert Bradway

Repatha and other recently launched meds helped boost Amgen's revenues by 6% to $23 billion, as well as CEO Robert Bradway's compensation by 4.7% to $16.5 million.
Regeneron

4. Leonard “Len” Schleifer

Regeneron's Praluent lagged far behind sales expectations, and it lost a patent trial. Company shares began to slide in late 2016, and that’s why Len Schleifer’s pay declined in 2016.